• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by TuHURA Biosciences Inc.

    6/13/25 6:15:06 AM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HURA alert in real time by email
    SEC FORM D

    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
    The reader should not assume that the information is accurate and complete.

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM D

    Notice of Exempt Offering of Securities

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated average burden
    hours per response: 4.00

    1. Issuer's Identity

    CIK (Filer ID Number) Previous Names
       None
    Entity Type
    0001498382
    Kintara Therapeutics, Inc.
    DelMar Pharmaceuticals, Inc.
    Berry Only Inc.
    X Corporation
       Limited Partnership
       Limited Liability Company
       General Partnership
       Business Trust
       Other (Specify)

    Name of Issuer
    TuHURA Biosciences, Inc./NV
    Jurisdiction of Incorporation/Organization
    NEVADA
    Year of Incorporation/Organization
    X Over Five Years Ago
       Within Last Five Years (Specify Year)
       Yet to Be Formed

    2. Principal Place of Business and Contact Information

    Name of Issuer
    TuHURA Biosciences, Inc./NV
    Street Address 1 Street Address 2
    10500 University Dr., Suite 110
    City State/Province/Country ZIP/PostalCode Phone Number of Issuer
    Tampa FLORIDA 33612 (813) 875-6600

    3. Related Persons

    Last Name First Name Middle Name
    Bianco James
    Street Address 1 Street Address 2
    10500 University Dr., Suite 110
    City State/Province/Country ZIP/PostalCode
    Tampa FLORIDA 33612
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Manuso James
    Street Address 1 Street Address 2
    10500 University Dr., Suite 110
    City State/Province/Country ZIP/PostalCode
    Tampa FLORIDA 33612
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Ng George
    Street Address 1 Street Address 2
    10500 University Dr., Suite 110
    City State/Province/Country ZIP/PostalCode
    Tampa FLORIDA 33612
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    List Alan
    Street Address 1 Street Address 2
    10500 University Dr., Suite 110
    City State/Province/Country ZIP/PostalCode
    Tampa FLORIDA 33612
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Hoffman Robert
    Street Address 1 Street Address 2
    10500 University Dr., Suite 110
    City State/Province/Country ZIP/PostalCode
    Tampa FLORIDA 33612
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Tendler Craig
    Street Address 1 Street Address 2
    10500 University Dr., Suite 110
    City State/Province/Country ZIP/PostalCode
    Tampa FLORIDA 33612
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Dearborn Dan
    Street Address 1 Street Address 2
    10500 University Dr., Suite 110
    City State/Province/Country ZIP/PostalCode
    Tampa FLORIDA 33612
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    4. Industry Group

       Agriculture
    Banking & Financial Services
       Commercial Banking
       Insurance
       Investing
       Investment Banking
       Pooled Investment Fund
    Is the issuer registered as
    an investment company under
    the Investment Company
    Act of 1940?
       Yes    No
       Other Banking & Financial Services
       Business Services
    Energy
       Coal Mining
       Electric Utilities
       Energy Conservation
       Environmental Services
       Oil & Gas
       Other Energy
    Health Care
    X Biotechnology
       Health Insurance
       Hospitals & Physicians
       Pharmaceuticals
       Other Health Care
       Manufacturing
    Real Estate
       Commercial
       Construction
       REITS & Finance
       Residential
       Other Real Estate
      
    Retailing
      
    Restaurants
    Technology
       Computers
       Telecommunications
       Other Technology
    Travel
       Airlines & Airports
       Lodging & Conventions
       Tourism & Travel Services
       Other Travel
      
    Other

    5. Issuer Size

    Revenue Range OR Aggregate Net Asset Value Range
       No Revenues    No Aggregate Net Asset Value
       $1 - $1,000,000    $1 - $5,000,000
       $1,000,001 - $5,000,000    $5,000,001 - $25,000,000
       $5,000,001 - $25,000,000    $25,000,001 - $50,000,000
       $25,000,001 - $100,000,000    $50,000,001 - $100,000,000
       Over $100,000,000    Over $100,000,000
    X Decline to Disclose    Decline to Disclose
       Not Applicable    Not Applicable

    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

       Rule 504(b)(1) (not (i), (ii) or (iii))
       Rule 504 (b)(1)(i)
       Rule 504 (b)(1)(ii)
       Rule 504 (b)(1)(iii)
    X Rule 506(b)
       Rule 506(c)
       Securities Act Section 4(a)(5)
       Investment Company Act Section 3(c)
       Section 3(c)(1)    Section 3(c)(9)  
       Section 3(c)(2)    Section 3(c)(10)
       Section 3(c)(3)    Section 3(c)(11)
       Section 3(c)(4)    Section 3(c)(12)
       Section 3(c)(5)    Section 3(c)(13)
       Section 3(c)(6)    Section 3(c)(14)
       Section 3(c)(7)

    7. Type of Filing

    X New Notice Date of First Sale 2025-06-02    First Sale Yet to Occur
       Amendment

    8. Duration of Offering

    Does the Issuer intend this offering to last more than one year?
       Yes X No

    9. Type(s) of Securities Offered (select all that apply)

    X Equity    Pooled Investment Fund Interests
       Debt    Tenant-in-Common Securities
    X Option, Warrant or Other Right to Acquire Another Security    Mineral Property Securities
    X Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security    Other (describe)

    10. Business Combination Transaction

    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
       Yes X No

    Clarification of Response (if Necessary):

    11. Minimum Investment

    Minimum investment accepted from any outside investor $0 USD

    12. Sales Compensation

    Recipient
    Recipient CRD Number    None
    Paulson Investment Company, LLC 5670
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    None None
    Street Address 1 Street Address 2
    10220 SW Greenburg Rd. Suite 380
    City State/Province/Country ZIP/Postal Code
    Portland OREGON 97223
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
       All States
       Foreign/non-US
    CALIFORNIA
    COLORADO
    CONNECTICUT
    FLORIDA
    NEW YORK
    PENNSYLVANIA
    SOUTH DAKOTA
    TEXAS
    VIRGINIA

    Recipient
    Recipient CRD Number    None
    Brookline Capital Markets, a division of Arcadia Securities, LLC 44656
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    None None
    Street Address 1 Street Address 2
    1370 Avenue of the Americas 29th Floor
    City State/Province/Country ZIP/Postal Code
    New York NEW YORK 10019
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
       All States
       Foreign/non-US
    ILLINOIS
    NEW YORK

    13. Offering and Sales Amounts

    Total Offering Amount $12,612,120 USD
    or    Indefinite
    Total Amount Sold $2,228,043 USD
    Total Remaining to be Sold $10,384,077 USD
    or    Indefinite

    Clarification of Response (if Necessary):

    14. Investors

      
    Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
    Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    36

    15. Sales Commissions & Finder's Fees Expenses

    Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

    Sales Commissions $948,073 USD
       Estimate
    Finders' Fees $0 USD
       Estimate

    Clarification of Response (if Necessary):

    16. Use of Proceeds

    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

    $0 USD
       Estimate

    Clarification of Response (if Necessary):

    Signature and Submission

    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

    Terms of Submission

    In submitting this notice, each issuer named above is:
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

    Issuer Signature Name of Signer Title Date
    TuHURA Biosciences, Inc./NV /s/ Dan Dearborn Dan Dearborn Chief Financial Officer 2025-06-12

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

    * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


    Get the next $HURA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HURA

    DatePrice TargetRatingAnalyst
    3/3/2025$13.00Buy
    H.C. Wainwright
    12/19/2024$11.00Buy
    Rodman & Renshaw
    11/5/2024$15.00Buy
    Maxim Group
    More analyst ratings

    $HURA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Tendler Craig

      4 - TuHURA Biosciences, Inc./NV (0001498382) (Issuer)

      3/19/25 7:13:50 PM ET
      $HURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Tendler Craig claimed no ownership of stock in the company (SEC Form 3)

      3 - TuHURA Biosciences, Inc./NV (0001498382) (Issuer)

      3/19/25 7:12:21 PM ET
      $HURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Hoffman Robert E.

      4 - TuHURA Biosciences, Inc./NV (0001498382) (Issuer)

      1/6/25 5:08:15 PM ET
      $HURA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HURA
    Financials

    Live finance-specific insights

    See more
    • TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

      Phase 3 IFx-2.0 accelerated approval trial as adjunctive therapy with Keytruda® (pembrolizumab) in 1st line therapy for advanced Merkel cell carcinoma (MCC) planning to initiate enrollment in Q2 2025 MCC Phase 3 trial to be conducted under Special Protocol Assessment (SPA) Agreement with FDA Acquisition of Kineta's Phase 2 ready, VISTA inhibiting antibody targeted for completion in Q2 2025 Expanded discovery team for first-in-class immune modulating Antibody Drug or Peptide Conjugate Program TAMPA, Fla., April 1, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overco

      4/1/25 8:00:00 AM ET
      $HURA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HURA
    SEC Filings

    See more
    • SEC Form D filed by TuHURA Biosciences Inc.

      D - TuHURA Biosciences, Inc./NV (0001498382) (Filer)

      6/13/25 6:15:06 AM ET
      $HURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TuHURA Biosciences Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)

      6/12/25 7:00:25 AM ET
      $HURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 425 filed by TuHURA Biosciences Inc.

      425 - TuHURA Biosciences, Inc./NV (0001498382) (Filed by)

      6/6/25 4:46:05 PM ET
      $HURA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HURA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by TuHURA Biosciences Inc.

      SC 13G - TuHURA Biosciences, Inc./NV (0001498382) (Subject)

      10/25/24 4:30:14 PM ET
      $HURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by TuHURA Biosciences Inc.

      SC 13G - TuHURA Biosciences, Inc./NV (0001498382) (Subject)

      10/25/24 4:28:34 PM ET
      $HURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by TuHURA Biosciences Inc.

      SC 13G - TuHURA Biosciences, Inc./NV (0001498382) (Subject)

      10/25/24 4:26:02 PM ET
      $HURA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HURA
    Leadership Updates

    Live Leadership Updates

    See more
    • TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management

      Proven 20-year career in drug discovery and development track record leading to 12 pre-clinical/clinical candidates and 7 investigational new drug / clinical trial applications Extensive knowledge in the biochemistry and pharmacology of the Delta Opioid Receptor (DOR), the primary target in TuHURA's Antibody Drug Conjugate (ADC) and Antibody Peptide Conjugate (APC) technology platform Inventor of first-in-class spirocyclic DOR agonists as potential analgesics; clinical- stage products licensed to Pfizer Led the benevopran opioid-induced bowel dysfunction program to positive Phase IIb results: key value inflection point resulting in the acquisition of Adolor Corporation by Cubist Pharmaceutic

      4/7/25 8:24:00 AM ET
      $HURA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HURA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on TuHURA Biosciences with a new price target

      H.C. Wainwright initiated coverage of TuHURA Biosciences with a rating of Buy and set a new price target of $13.00

      3/3/25 7:23:43 AM ET
      $HURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rodman & Renshaw initiated coverage on TuHURA Biosciences with a new price target

      Rodman & Renshaw initiated coverage of TuHURA Biosciences with a rating of Buy and set a new price target of $11.00

      12/19/24 7:41:52 AM ET
      $HURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maxim Group initiated coverage on TuHURA Biosciences with a new price target

      Maxim Group initiated coverage of TuHURA Biosciences with a rating of Buy and set a new price target of $15.00

      11/5/24 7:54:57 AM ET
      $HURA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HURA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • FDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma

      Company anticipates initiating its Phase 3 accelerated approval trial of IFx-Hu2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as first-line treatment for advanced and metastatic Merkel cell carcinoma (MCC), conducted under Special Protocol Assessment (SPA) Agreement with U.S. Food and Drug Administration (FDA), later in June 2025 Resolution of partial clinical hold unlocks second tranche of funds from $12.5 million PIPE financing announced on June 3, 2025 TAMPA, Fla., June 9, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today an

      6/9/25 8:00:00 AM ET
      $HURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer Immunotherapy

      Secures $12.5 million of commitments in a private offering Secures an additional $3.0 million through payment of cash exercise price of warrants Funding provides capital for: Initiation of planned Phase 3 accelerated approval trial of IFx-2.0 targeting 40% enrollment by 2-2025 year endAcquisition of and initiating a Phase 2 trial in NPM1 mutated AML, a novel VISTA inhibiting antibody through closing of Kineta mergerAdvancing first-in-class immune modulating bi-specific, and bi-functional Antibody Drug Conjugates (ADC) and Antibody Peptide Conjugates (APCs)TAMPA, Fla., June 3, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or "Company"), a Phase 3 immune-oncology compan

      6/3/25 9:58:00 AM ET
      $HURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual Meeting

      Phase 3 IFx-Hu2.0 trial as an adjunctive therapy with Keytruda® (pembrolizumab) in checkpoint inhibitor (CPI)-naïve patients with advanced or metastatic Merkel cell carcinoma (MCC) detailed in Trial in Progress Poster at ASCO Phase 3 trial of IFx-Hu2.0 to be conducted under Accelerated Approval Pathway and Special Protocol Assessment (SPA) agreement with U.S. Food and Drug Administration (FDA) TAMPA, Fla., June 2, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that Moffitt Cancer Center presented a Trial in Progress poster of the Company's p

      6/2/25 8:03:00 AM ET
      $HURA
      Biotechnology: Pharmaceutical Preparations
      Health Care